Crossmark

Abemaciclib adjuvant bei Mammakarzinom möglich

Crossref DOI link: https://doi.org/10.1007/s15004-025-1184-6

Published Online: 2025-11-17

Published Print: 2025-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Facharztmagazine, Redaktion
License Information

Text and Data Mining valid from 2025-11-01

Version of Record valid from 2025-11-01
More Information

Article History

First Online: 17 November 2025

Free to read: This content has been made available to all.